Multiple signal pathways in obesity-associated cancer

Area of Science:

• Oncology
• Metabolic Syndrome
• Molecular Biology

Background:

• Obesity is a global health crisis linked to increased cancer incidence.
• Obesity-associated cancers pose a significant public health challenge.
• Existing research on obesity's impact on cancer signaling pathways remains controversial.

Purpose of the Study:

• To review and synthesize recent findings on intracellular signal pathways implicated in obesity-associated cancer.
• To provide a unified explanation for the complex roles of these pathways.
• To explore potential therapeutic strategies targeting these pathways.

Main Methods:

• Literature review of recent studies on signal pathways in obesity-associated cancer.
• Analysis of the interplay between obesity risk factors and intracellular signaling.
• Examination of the roles of phosphoinositide 3-kinase (PI3K/Akt), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and mammalian target of rapamycin (mTOR) pathways.

Main Results:

• Obesity risk factors initially activate PI3K/Akt, MAPK, and STAT3 pathways.
• As obesity severity increases, mammalian target of rapamycin (mTOR) becomes highly activated.
• Activated mTOR inhibits PI3K/Akt while further activating STAT3, explaining pathway dynamics in obesity.
• This dynamic suggests PI3K/Akt activation in early obesity and inhibition in later stages.

Conclusions:

• The complex interplay of signaling pathways in obesity-driven cancer requires a nuanced therapeutic approach.
• Targeting mammalian target of rapamycin (mTOR) shows promise for cancer therapy.
• Combined inhibition of PI3K and mTOR may offer a novel therapeutic strategy for obesity-associated cancers, overcoming feedback inhibition mechanisms.